These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 33452421)
1. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Chu SS; Kuo YH; Liu WS; Wang SC; Ho CH; Chen YC; Yang CC; Wu HC Sci Rep; 2021 Jan; 11(1):1614. PubMed ID: 33452421 [TBL] [Abstract][Full Text] [Related]
2. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014. Opneja A; Cioffi G; Alahmadi A; Jones N; Tang TY; Patil N; Bajor DL; Saltzman JN; Mohamed A; Selfridge E; Mangla A; Barnholtz-Sloan J; Lee RT Cancer Med; 2021 Jul; 10(13):4397-4404. PubMed ID: 34060249 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G; Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679 [TBL] [Abstract][Full Text] [Related]
4. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556 [TBL] [Abstract][Full Text] [Related]
5. Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma. Zhu H; Ye B; Qiao Z; Zeng L; Li Q J BUON; 2019; 24(4):1382-1389. PubMed ID: 31646781 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T; Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348 [TBL] [Abstract][Full Text] [Related]
7. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
8. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Fang JH; Xu L; Shang LR; Pan CZ; Ding J; Tang YQ; Liu H; Liu CX; Zheng JL; Zhang YJ; Zhou ZG; Xu J; Zheng L; Chen MS; Zhuang SM Hepatology; 2019 Sep; 70(3):824-839. PubMed ID: 30506570 [TBL] [Abstract][Full Text] [Related]
9. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282 [TBL] [Abstract][Full Text] [Related]
10. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Chen L; Su H; Shao H; Xu K; Liang S; Liu J Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Estfan B; Byrne M; Kim R Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010 [TBL] [Abstract][Full Text] [Related]
12. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157 [TBL] [Abstract][Full Text] [Related]
13. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579 [TBL] [Abstract][Full Text] [Related]
14. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T; Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880 [TBL] [Abstract][Full Text] [Related]
16. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513 [TBL] [Abstract][Full Text] [Related]
18. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. Ruanglertboon W; Sorich MJ; Logan JM; Rowland A; Hopkins AM J Cancer Res Clin Oncol; 2020 Oct; 146(10):2693-2697. PubMed ID: 32449002 [TBL] [Abstract][Full Text] [Related]
19. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Tsukui Y; Mochizuki H; Hoshino Y; Kawakami S; Kuno T; Fukasawa Y; Iwamoto F; Hirose S; Yoshida T; Hosoda K; Suzuki Y; Hosoda K; Kojima Y; Hirose Y; Shindou K; Matsuda M; Yagawa S; Tawara A; Kobayashi M; Konishi T; Yamazaki T; Takahashi S; Fuji H; Enomoto N; Omata M Hepatogastroenterology; 2012; 59(120):2536-9. PubMed ID: 22497953 [TBL] [Abstract][Full Text] [Related]
20. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]